Novartis has announced that it is discontinuing a Phase 3 trial of the drug, Tasigna (nilotinib), for the first-line treatment of gastrointestinal stromal tumours (GIST) on the advice of an independent data monitoring committee. ---Subscribe to MedNous to access this article--- Company News
